Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Robab Hassanvand Jamadi"'
Autor:
Robab Hassanvand Jamadi, Moslem Jafarisani, Zahra Sadat Hashemi, Maysam Mard-Soltani, Tooba Mirzapour, Saeed Khalili, Hashem Yaghoubi
Publikováno v:
International Journal of Peptide Research and Therapeutics. 26:1013-1020
Human chronic myelogenous leukemia (CML) is a stem cell driven hematological malignancy which shows resistance to existing therapeutics. This property of CML accentuates the necessity to develop alternative anti-CML therapeutic agents. Herein, we hav
Publikováno v:
International Journal of Peptide Research and Therapeutics. 25:1225-1239
Our study aims to establish a biocompatible nanostructure for the improved delivery of anticancer peptide, Brevinin-2R, to treat human gastric adenocarcinoma (AGS), human liver hepatocellular carcinoma (HepG2) and human squamous cell carcinoma (KYSE-
Publikováno v:
International Journal of Peptide Research and Therapeutics. 25:151-160
Brevinin-2R (BR-2R), a novel antimicrobial and anti-cancer peptide and two derivatives, BR-C and BR-D, were well designed, synthesized and purified by RP-HPLC (reverse phase high pressure chromatography). Accuracy was confirmed through mass spectrome
Autor:
Haniyeh Eyvani, Farinaz Barghi, Ardeshir Ghavamzadeh, Azam Zaghal, Fazel Sahraneshin Samani, Majid Momeny, Seyed H. Ghaffari, Ahmad Reza Dehpour, Parisa Ghaffari, Davood Bashash, Seyyed Mohammad Tavangar, Fatemeh Esmaeili, Zivar Alishahi, Sepehr Javadikooshesh, Robab Hassanvand Jamadi, Kamran Alimoghaddam
Publikováno v:
Anti-cancer drugs. 29(10)
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy worldwide. Development of chemoresistance and peritoneal dissemination are the major reasons for low survival rate in the patients. The bromodomain and extraterminal domain (
Publikováno v:
AAPS PharmSciTech. 19(4)
The aim of this study was an in vitro evaluation and comparison of the cytotoxic effects of free nisin and nisin-loaded PLA-PEG-PLA nanoparticles on gastrointestinal (AGS and KYSE-30), hepatic (HepG2), and blood (K562) cancer cell lines. To create th